These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results. Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y; Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545 [TBL] [Abstract][Full Text] [Related]
6. Adjuvant and neoadjuvant therapies in high risk localized prostate cancer. Giannakopoulos X; Stagikas D; Charalabopoulos A; Sofikitis N; Charalabopoulos K J Exp Clin Cancer Res; 2006 Dec; 25(4):469-73. PubMed ID: 17310835 [TBL] [Abstract][Full Text] [Related]
7. Predictors of secondary cancer treatment in patients receiving local therapy for prostate cancer: data from cancer of the prostate strategic urologic research endeavor. Grossfeld GD; Li YP; Lubeck DP; Broering JM; Mehta SS; Carroll PR J Urol; 2002 Aug; 168(2):530-5. PubMed ID: 12131303 [TBL] [Abstract][Full Text] [Related]
8. Adjuvant therapy for prostate cancer patients at high risk of recurrence following radical prostatectomy. Andriole GL Eur Urol; 1997; 32 Suppl 3():65-9. PubMed ID: 9267788 [TBL] [Abstract][Full Text] [Related]
9. [Is maximal androgenic blockade necessary in the treatment of prostatic cancer?]. Matveev BP; Bukharkin BV Urologiia; 2003; (6):6-10. PubMed ID: 14708235 [TBL] [Abstract][Full Text] [Related]
10. Diagnostic evaluation of PSA recurrence and review of hormonal management after radical prostatectomy. Van Poppel H; Joniau S; Van Cleynenbreugel B; Mottaghy FM; Oyen R Prostate Cancer Prostatic Dis; 2009; 12(2):116-23. PubMed ID: 19238169 [TBL] [Abstract][Full Text] [Related]
11. Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer. Hennenfent BR Br J Urol; 1998 Jul; 82(1):166. PubMed ID: 9698691 [No Abstract] [Full Text] [Related]
12. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378 [TBL] [Abstract][Full Text] [Related]
13. Prostate specific antigen doubling time after radical prostatectomy: effect of neoadjuvant androgen deprivation therapy. Rabbani F; Perrotti M; Bastar A; Fair WR J Urol; 1999 Mar; 161(3):847-52. PubMed ID: 10022699 [TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant total androgen suppression and radiotherapy in the management of locally advanced prostate cancer. Roach M Semin Urol Oncol; 1996 May; 14(2 Suppl 2):32-7; discussion 38. PubMed ID: 8725889 [TBL] [Abstract][Full Text] [Related]
15. Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer. Wieder JA; Soloway MS J Urol; 1998 Aug; 160(2):299-315. PubMed ID: 9679867 [TBL] [Abstract][Full Text] [Related]